85 related articles for article (PubMed ID: 25565673)
1. Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations.
Robertsen I; Vethe NT; Midtvedt K; Falck P; Christensen H; Åsberg A
Ther Drug Monit; 2015 Oct; 37(5):675-80. PubMed ID: 25565673
[TBL] [Abstract][Full Text] [Related]
2. A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators.
Robertsen I; Debord J; Åsberg A; Marquet P; Woillard JB
Clin Pharmacokinet; 2018 Nov; 57(11):1459-1469. PubMed ID: 29556934
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.
Lemaitre F; Bezian E; Goldwirt L; Fernandez C; Farinotti R; Varnous S; Urien S; Antignac M
Ther Drug Monit; 2012 Dec; 34(6):686-94. PubMed ID: 23131698
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients.
Lemaitre F; Antignac M; Fernandez C
Clin Biochem; 2013 Oct; 46(15):1538-41. PubMed ID: 23454394
[TBL] [Abstract][Full Text] [Related]
5. Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers.
Ansermot N; Rebsamen M; Chabert J; Fathi M; Gex-Fabry M; Daali Y; Besson M; Rossier M; Rudaz S; Hochstrasser D; Dayer P; Desmeules J
Drug Metab Lett; 2008 Apr; 2(2):76-82. PubMed ID: 19356075
[TBL] [Abstract][Full Text] [Related]
6. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.
Capron A; Mourad M; De Meyer M; De Pauw L; Eddour DC; Latinne D; Elens L; Haufroid V; Wallemacq P
Pharmacogenomics; 2010 May; 11(5):703-14. PubMed ID: 20415563
[TBL] [Abstract][Full Text] [Related]
7. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation.
Moes DJ; Press RR; de Fijter JW; Guchelaar HJ; den Hartigh J
Ther Drug Monit; 2010 Aug; 32(4):413-9. PubMed ID: 20535052
[TBL] [Abstract][Full Text] [Related]
8. Comparative transcriptome analysis of peripheral blood mononuclear cells in renal transplant recipients in everolimus- and tacrolimus-based immunosuppressive therapy.
Granata S; Santoro G; Signorini L; Malerba G; Patuzzo C; Gambaro G; Stallone G; Zaza G
Eur J Pharmacol; 2019 Sep; 859():172494. PubMed ID: 31238062
[TBL] [Abstract][Full Text] [Related]
9. Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study.
Llaudó I; Colom H; Giménez-Bonafé P; Torras J; Caldés A; Sarrias M; Cruzado JM; Oppenheimer F; Sánchez-Plumed J; Gentil MÁ; Ekberg H; Grinyó JM; Lloberas N
Transpl Int; 2013 Feb; 26(2):177-86. PubMed ID: 23216707
[TBL] [Abstract][Full Text] [Related]
10. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Ansermot N; Fathi M; Pascual M; Eap CB
Pharmacogenet Genomics; 2008 Apr; 18(4):307-15. PubMed ID: 18334915
[TBL] [Abstract][Full Text] [Related]
11. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?
Singh R; Srivastava A; Kapoor R; Mittal RD
J Clin Pharmacol; 2011 Apr; 51(4):603-15. PubMed ID: 20571034
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus.
Vafadari R; Bouamar R; Hesselink DA; Kraaijeveld R; van Schaik RH; Weimar W; Baan CC; van Gelder T
Ther Drug Monit; 2013 Aug; 35(4):459-65. PubMed ID: 23743668
[TBL] [Abstract][Full Text] [Related]
13. Comparison of electrochemiluminescence immunoassay and latex agglutination turbidimetric immunoassay for evaluation of everolimus blood concentrations in renal transplant patients.
Akamine Y; Sato S; Kagaya H; Ohkubo T; Satoh S; Miura M
J Clin Pharm Ther; 2018 Oct; 43(5):675-681. PubMed ID: 29679392
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.
Estrela Rde C; Ribeiro FS; Barroso PF; Tuyama M; Gregório SP; Dias-Neto E; Struchiner CJ; Suarez-Kurtz G
Pharmacogenomics; 2009 Feb; 10(2):311-8. PubMed ID: 19207033
[TBL] [Abstract][Full Text] [Related]
15. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients.
Bandur S; Petrasek J; Hribova P; Novotna E; Brabcova I; Viklicky O
Transplantation; 2008 Nov; 86(9):1206-13. PubMed ID: 19005401
[TBL] [Abstract][Full Text] [Related]
16. Analytical performance of QMS everolimus assay on ortho Vitros 5,1 FS fusion analyzer: measuring everolimus trough levels for solid organ transplant recipients.
Shu I; Wright AM; Chandler WL; Bernard DW; Wang P
Ther Drug Monit; 2014 Apr; 36(2):264-8. PubMed ID: 24232125
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine monitoring in peripheral blood mononuclear cells: feasibility and interest. A prospective study on 20 renal transplant recipients.
Lepage JM; Lelong-Boulouard V; Lecouf A; Debruyne D; Hurault de Ligny B; Coquerel A
Transplant Proc; 2007 Dec; 39(10):3109-10. PubMed ID: 18089333
[TBL] [Abstract][Full Text] [Related]
18. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients.
Akbas SH; Bilgen T; Keser I; Tuncer M; Yucetin L; Tosun O; Gultekin M; Luleci G
Transplant Proc; 2006 Jun; 38(5):1290-2. PubMed ID: 16797284
[TBL] [Abstract][Full Text] [Related]
19. Comparison of everolimus QMS immunoassay on Architect ci4100 and liquid chromatography/mass spectrometry: lack of agreement in organ-transplanted patients.
Hoffer E; Kurnik D; Efrati E; Scherb I; Karasik M; Ring G; Bentur Y
Ther Drug Monit; 2015 Apr; 37(2):214-9. PubMed ID: 25162218
[TBL] [Abstract][Full Text] [Related]
20. Opportunity to monitor immunosuppressive drugs in peripheral blood mononuclear cells: where are we and where are we going?
Lemaitre F; Antignac M; Verdier MC; Bellissant E; Fernandez C
Pharmacol Res; 2013 Aug; 74():109-12. PubMed ID: 23792083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
